Further positive MDMA analogue screening results received
Filed with ASX · · 4 pages · English
● Emyria and the University of Western Australia (UWA) have received positive screening results from the second batch of MDMA analogues sent to Eurofins (EPA:ERF) ● 16 of 17 novel compounds synthesised and screened demonstrated no interactions with selected “anti-targets” (receptors and enzymes known to be involved in unwanted side effects); These results bring total count of successfully screened
Story so far
Earlier from Emyria
- Broker Briefing Presentation
- Emyria launches second ultra-pure CBD capsule
- Recruitment commenced for EMD-RX5 Phase 1 Study
- Ethics approval received for EMD-RX5 Phase 1 Study
- Emyria grows its novel MDMA-analogue library
Later from Emyria
- EMD-RX5 demonstrates excellent safety and bioavailability
- Emyria expands MDMA analogue program with UWA
- Emyria expands drug candidate library inspired by MDMA
- Appendix 4C - Quarterly
- Preclinical studies initiated for MDMA-inspired analogues
Follow Emyria into a list and get an email when it puts out news.
Follow Emyria